vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与UNITED STATES LIME & MINERALS INC（USLM）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是UNITED STATES LIME & MINERALS INC的1.7倍（$152.6M vs $87.9M），UNITED STATES LIME & MINERALS INC净利率更高（34.7% vs 34.5%，领先0.2%），UNITED STATES LIME & MINERALS INC同比增速更快（9.8% vs 7.6%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $25.7M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 10.8%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
美国石灰矿产公司是总部位于美国的自然资源企业，主营高钙石灰、白云石石灰、石灰石及相关矿产制品，客户覆盖基建、钢铁制造、农业土壤改良、环保排放治理、工业加工等领域，业务主要辐射北美市场。
CPRX vs USLM — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $87.9M |
| 净利润 | $52.7M | $30.5M |
| 毛利率 | 82.9% | 48.0% |
| 营业利润率 | 40.5% | 41.0% |
| 净利率 | 34.5% | 34.7% |
| 营收同比 | 7.6% | 9.8% |
| 净利润同比 | -5.8% | 13.2% |
| 每股收益（稀释后） | $0.40 | $1.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $87.9M | ||
| Q3 25 | $148.4M | $102.0M | ||
| Q2 25 | $146.6M | $91.5M | ||
| Q1 25 | $141.4M | $91.3M | ||
| Q4 24 | $141.8M | $80.1M | ||
| Q3 24 | $128.7M | $89.4M | ||
| Q2 24 | $122.7M | $76.5M | ||
| Q1 24 | $98.5M | $71.7M |
| Q4 25 | $52.7M | $30.5M | ||
| Q3 25 | $52.8M | $38.8M | ||
| Q2 25 | $52.1M | $30.8M | ||
| Q1 25 | $56.7M | $34.1M | ||
| Q4 24 | $55.9M | $27.0M | ||
| Q3 24 | $43.9M | $33.4M | ||
| Q2 24 | $40.8M | $26.1M | ||
| Q1 24 | $23.3M | $22.4M |
| Q4 25 | 82.9% | 48.0% | ||
| Q3 25 | 84.7% | 51.2% | ||
| Q2 25 | 85.9% | 45.8% | ||
| Q1 25 | 87.3% | 50.6% | ||
| Q4 24 | 84.7% | 44.3% | ||
| Q3 24 | 85.0% | 48.2% | ||
| Q2 24 | 87.4% | 45.5% | ||
| Q1 24 | 87.3% | 42.7% |
| Q4 25 | 40.5% | 41.0% | ||
| Q3 25 | 44.7% | 45.3% | ||
| Q2 25 | 45.2% | 39.0% | ||
| Q1 25 | 44.8% | 43.7% | ||
| Q4 24 | 44.3% | 38.8% | ||
| Q3 24 | 39.6% | 42.6% | ||
| Q2 24 | 44.2% | 39.1% | ||
| Q1 24 | 27.5% | 35.9% |
| Q4 25 | 34.5% | 34.7% | ||
| Q3 25 | 35.6% | 38.0% | ||
| Q2 25 | 35.6% | 33.7% | ||
| Q1 25 | 40.1% | 37.4% | ||
| Q4 24 | 39.4% | 33.7% | ||
| Q3 24 | 34.1% | 37.3% | ||
| Q2 24 | 33.2% | 34.0% | ||
| Q1 24 | 23.6% | 31.3% |
| Q4 25 | $0.40 | $1.06 | ||
| Q3 25 | $0.42 | $1.35 | ||
| Q2 25 | $0.41 | $1.07 | ||
| Q1 25 | $0.45 | $1.19 | ||
| Q4 24 | $0.44 | $-2.20 | ||
| Q3 24 | $0.35 | $1.16 | ||
| Q2 24 | $0.33 | $0.91 | ||
| Q1 24 | $0.19 | $3.92 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $371.1M |
| 总债务越低越好 | — | $0 |
| 股东权益账面价值 | $954.3M | $630.8M |
| 总资产 | $1.1B | $681.0M |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $371.1M | ||
| Q3 25 | $689.9M | $349.5M | ||
| Q2 25 | $652.8M | $319.9M | ||
| Q1 25 | $580.7M | $300.6M | ||
| Q4 24 | $517.6M | $278.0M | ||
| Q3 24 | $442.3M | $255.0M | ||
| Q2 24 | $375.7M | $222.5M | ||
| Q1 24 | $310.4M | $207.0M |
| Q4 25 | — | $0 | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | $954.3M | $630.8M | ||
| Q3 25 | $920.2M | $602.3M | ||
| Q2 25 | $856.0M | $563.3M | ||
| Q1 25 | $794.3M | $532.2M | ||
| Q4 24 | $727.6M | $497.7M | ||
| Q3 24 | $660.9M | $474.2M | ||
| Q2 24 | $608.7M | $441.1M | ||
| Q1 24 | $561.4M | $415.3M |
| Q4 25 | $1.1B | $681.0M | ||
| Q3 25 | $1.1B | $652.8M | ||
| Q2 25 | $971.9M | $607.4M | ||
| Q1 25 | $908.9M | $585.3M | ||
| Q4 24 | $851.4M | $543.2M | ||
| Q3 24 | $772.0M | $521.8M | ||
| Q2 24 | $706.4M | $484.2M | ||
| Q1 24 | $646.7M | $464.0M |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $45.6M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $25.7M |
| 自由现金流率自由现金流/营收 | 29.4% | 29.2% |
| 资本支出强度资本支出/营收 | 0.0% | 22.6% |
| 现金转化率经营现金流/净利润 | 0.85× | 1.49× |
| 过去12个月自由现金流最近4个季度 | — | $102.3M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $45.6M | ||
| Q3 25 | $32.4M | $45.9M | ||
| Q2 25 | $71.3M | $34.0M | ||
| Q1 25 | $60.0M | $39.4M | ||
| Q4 24 | $70.9M | $38.6M | ||
| Q3 24 | $72.9M | $39.0M | ||
| Q2 24 | $64.1M | $21.2M | ||
| Q1 24 | $31.9M | $27.2M |
| Q4 25 | $44.9M | $25.7M | ||
| Q3 25 | — | $31.3M | ||
| Q2 25 | $71.3M | $20.8M | ||
| Q1 25 | — | $24.6M | ||
| Q4 24 | $70.8M | $27.6M | ||
| Q3 24 | $72.6M | $33.9M | ||
| Q2 24 | $64.1M | $16.8M | ||
| Q1 24 | $31.7M | $20.3M |
| Q4 25 | 29.4% | 29.2% | ||
| Q3 25 | — | 30.7% | ||
| Q2 25 | 48.6% | 22.7% | ||
| Q1 25 | — | 26.9% | ||
| Q4 24 | 49.9% | 34.4% | ||
| Q3 24 | 56.4% | 37.9% | ||
| Q2 24 | 52.3% | 21.9% | ||
| Q1 24 | 32.2% | 28.4% |
| Q4 25 | 0.0% | 22.6% | ||
| Q3 25 | 0.0% | 14.4% | ||
| Q2 25 | 0.0% | 14.5% | ||
| Q1 25 | 0.0% | 16.3% | ||
| Q4 24 | 0.1% | 13.8% | ||
| Q3 24 | 0.2% | 5.8% | ||
| Q2 24 | 0.0% | 5.7% | ||
| Q1 24 | 0.2% | 9.5% |
| Q4 25 | 0.85× | 1.49× | ||
| Q3 25 | 0.61× | 1.18× | ||
| Q2 25 | 1.37× | 1.10× | ||
| Q1 25 | 1.06× | 1.16× | ||
| Q4 24 | 1.27× | 1.43× | ||
| Q3 24 | 1.66× | 1.17× | ||
| Q2 24 | 1.57× | 0.81× | ||
| Q1 24 | 1.37× | 1.21× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
USLM
暂无分部数据
